Fine Chemicals Firm AMRI Buys Excelsyn for $19 Million

Pharmaceutical ingredients manufacturer and drug discovery firm AMRI (Albany, NY) says it has acquired contract fine chemicals business Excelsyn (Holywell, U.K.) for $19 million. Excelsyn had been privately owned and led by industry veteran Ian Shott. AMRI says the deal will be Ebitda accretive to the group in 2010.   Excelsyn’s key activities include process development and manufacturing services for the pharmaceuticals industry. Manufacturing services include pre-clinical and phase I-III product development as well as commercial manufacturing of...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers